CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity

A large proportion (40–60%) of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer do not benefit from trastuzumab treatment, potentially due to the lack of complement-dependent cytotoxicity (CDC) activation. In the present study, the effect of complement decay...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Wang, Yu, Yang, Ya-Jun, Wang, Zhu, Liao, Juan, Liu, Mei, Zhong, Xiao-Rong, Zheng, Hong, Wang, Yan-Ping
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5588148/
https://ncbi.nlm.nih.gov/pubmed/28928834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6555
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados